Replies to post #117371 on Biotech Values

[gdollasign]

thanks for the insight ghmm.

As a side note, if we have decent participation, I will post the results and if any are curious, i will post my decided position(s).

[genisi]

BMRN/BMN 110 in Morquio A Syndrome

FWIW, I'm quite optimistic for GALNS phase III trial to be successful.

[iandy]

I do not think any list of risky biotech plays would be complete if it did not include what is (based on past events) probably the king of risky biotech plays - Elan.

1)The test for the virus related to PML should serve to mitigate the severity and frequency of cases of PML.
If the perceved safety of the drug improves as a result of less cases of PML and a reduction in the severity of the cases that do appear,Tysabri will be more prescribed in the treatment of both MS and Crohns disease.

2) Elan holds a 49.9% equity interest in JANSSEN Alzheimer Immunotherapy, and will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of (bapineuzumab), a potential first-in-class treatment that is
in phase 3 testing for Alzheimer's disease.
The phase 3 results should come out in the 2012-2013 timeframe.

JMHO and worth what you paid for it.